You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back


NUCALA is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.1

Nucala 100 mg sc compared to placebo, when both are added to standard of care:

  • Consistently reduced exacerbations across multiple studies*23
  • Consistently reduced hospitalisations and/or ED visits resulting from exacerbations across multiple studies**23
  • Reduced daily OCS dose by 50%4, and is the only biologic for severe refractory eosinophilic asthma with sustained OCS reduction for up to 1.5 years‡5

Discover more about the clinical data behind Nucala

Added to standard of care, NUCALA is available for a sub-popuation of severe refractory eosinophilic adult asthma patients. To identify which of your patients fall into this sub-population ensure they meet the following criteria6:

What is Nucala?

Nucala is a humanised monoclonal antibody that:

  • Blocks the binding of IL-5 to the eosinophil cell surface 1
  • Inhibits IL-5 signalling and the growth, activation and survival of eosinophils 7
  • Significantly reduces blood eosinophil levels 18
What is Nucala

Nucala Mode of Action

Watch a visual exploration of Nucala (mepolizumab) and its structure-function relationship.

ED, emergency department; OCS, oral corticosteroids

† Standard of care - High dose ICS and additional maintenance treatment(s)

* 53% exacerbation reduction vs. placebo at Week 32 of MENSA (0.83/year vs. 1.74/year; p<0.001)2; 58% exacerbation reduction vs. placebo at Week 24 of MUSCA (0.51/year vs. 1.21/year; p<0.0001)3.

** 61% reduction vs. placebo at Week 32 of MENSA (0.08/year vs. 0.20/year; p=0.02)2; 68% reduction vs. placebo at Week 24 of MUSCA (0.03/year vs. 0.10/year; p=0.031)3.

‡ Data from COSMOS, a 52-week, open-label extension study of the double-blind, 32-week MENSA and 24-week SIRIUS randomised controlled studies5 .


  1. Nucala Summary of Product Characteristics. Available from: Last accessed: March 2019.
  2. Ortega HG, Liu MC, Pavord ID, et al. N Engl J Med 2014; 371:1198-1207.
  3. Chupp GL et al. Lancet Respir Med 2017; 5:390-400.
  4. Bel EH et al. N Engl J Med 2014; 371:1189-1197.
  5. Lugogo N et al. Clin Ther 2016; 38:2058-2070.
  6. Last accessed: March 2019.
  7. Garcia G et al. Eur Respir Rev 2013; 22:251-257.
  8. Ortega HG et al. Eur Respir J 2014; 44:239-241.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

NUCALA is a registered trademark of the GlaxoSmithKline Group of Companies.